Step 2 CK Internal Medicine High Yield Cardiology
Hypertension Staging and Pharmacologic Management
Management of hypertension on Step 2 CK is governed by the JNC 8 or ACC/AHA guidelines, focusing on specific blood pressure thresholds and the presence of comorbid conditions. For most patients, the goal is less than 130/80 mmHg. When a patient presents with elevated readings, the exam often tests the requirement for two separate measurements at least two weeks apart before initiating therapy, unless the initial presentation involves a hypertensive urgency or emergency.
Pharmacologic selection is highly dependent on "compelling indications." For example, patients with diabetes mellitus or chronic kidney disease (CKD) should typically receive an ACE inhibitor or Angiotensin Receptor Blocker (ARB) to provide renal protection. In contrast, black patients without these comorbidities often show better responses to Calcium Channel Blockers (CCBs) or thiazide diuretics. You must also recognize contraindications; avoid beta-blockers as first-line therapy for uncomplicated hypertension, and never combine an ACE inhibitor with an ARB due to the risk of hyperkalemia and acute kidney injury. Understanding the side effect profiles, such as the peripheral edema associated with amlodipine or the dry cough from lisinopril, is essential for answering "best next step" questions when a patient fails initial therapy.
Heart Failure: Guideline-Directed Medical Therapy (GDMT)
Heart failure (HF) questions frequently require distinguishing between Heart Failure with reduced Ejection Fraction (HFrEF) and Heart Failure with preserved Ejection Fraction (HFpEF). The cornerstone of USMLE internal medicine review for HFrEF is understanding which medications actually provide a mortality benefit. The core triad includes ACE inhibitors/ARBs (or the ARNI sacubitril/valsartan), beta-blockers (specifically carvedilol, metoprolol succinate, or bisoprolol), and mineralocorticoid receptor antagonists like spironolactone.
Step 2 CK frequently tests the sequential addition of these agents. For instance, if a patient remains symptomatic on an ACE inhibitor and a beta-blocker with an EF <35%, the next step is often adding an aldosterone antagonist or switching the ACE inhibitor to an ARNI. You must also be familiar with the role of SGLT2 inhibitors, which have recently become a standard of care for HFrEF regardless of diabetes status. For acute decompensation, the focus shifts to diuresis with loop diuretics and the assessment of perfusion using the "warm/cold" and "wet/dry" clinical framework. Remember that beta-blockers should not be initiated or up-titrated during an acute exacerbation, though they are usually continued if the patient was already taking them stably.
Acute Coronary Syndrome Workup and Intervention
When a patient presents with chest pain, the first step is always an EKG, ideally performed within 10 minutes of arrival. Step 2 CK cardiology topics emphasize the differentiation between ST-elevation myocardial infarction (STEMI), NSTEMI, and unstable angina. For STEMI, the priority is immediate reperfusion. The exam will ask you to choose between Percutaneous Coronary Intervention (PCI) and fibrinolysis; PCI is preferred if it can be performed within 90 minutes at a PCI-capable center or 120 minutes if the patient requires transfer.
In the case of NSTEMI or unstable angina, the management is medical stabilization followed by risk stratification using the TIMI score. High-yield medications include dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (like clopidogrel or ticagrelor), anticoagulation (heparin), nitrates, and high-intensity statins. Be wary of using nitrates or morphine in patients with suspected right ventricular infarction (ST elevation in leads II, III, and aVF), as these patients are preload-dependent and may develop profound hypotension. In these scenarios, the correct management is a fluid bolus rather than vasodilators.
Gastroenterology and Hepatology Essentials
Screening and Surveillance for GI Malignancies
Step 2 CK gastroenterology high yield content heavily features the USPSTF guidelines for colorectal cancer (CRC) screening. For average-risk individuals, screening now begins at age 45 and continues until 75. Options include annual fecal immunochemical testing (FIT) or colonoscopy every 10 years. However, the exam focuses on when to screen earlier or more frequently. For patients with a first-degree relative diagnosed with CRC before age 60, screening should begin at age 40, or 10 years before the relative's diagnosis, whichever comes first, and repeat every 5 years.
Surveillance after a colonoscopy depends on the findings. A patient with 1-2 small tubular adenomas typically requires a repeat in 7-10 years, while those with high-risk features—such as >10 mm size, villous histology, or high-grade dysplasia—require a 3-year interval. You must also recognize the screening requirements for patients with Inflammatory Bowel Disease (IBD). For Ulcerative Colitis or Crohn’s involving the colon, surveillance colonoscopies with random biopsies are required starting 8 years after diagnosis and repeating every 1-2 years. Understanding these timing rules is a common way the exam assesses clinical preventative knowledge.
Management of Chronic Liver Disease and Complications
Questions regarding cirrhosis focus on the management of its sequelae: ascites, hepatic encephalopathy, and variceal bleeding. For ascites, the initial management is sodium restriction and a combination of spironolactone and furosemide (typically in a 100:40 ratio to maintain potassium balance). If a patient develops spontaneous bacterial peritonitis (SBP), diagnosed by an ascitic fluid polymorphonuclear (PMN) count ≥250/mm³, the treatment of choice is a third-generation cephalosporin like cefotaxime.
Hepatic encephalopathy is managed primarily by identifying the trigger (such as infection, GI bleed, or constipation) and administering lactulose to promote nitrogen excretion. For esophageal varices, primary prophylaxis with non-selective beta-blockers (e.g., nadolol or propranolol) or endoscopic band ligation is required if large varices are present. In the acute setting of a variceal bleed, the priority is hemodynamic stabilization, intravenous octreotide, and prophylactic antibiotics (ceftriaxone) to prevent SBP. The MELD score (Model for End-Stage Liver Disease), which utilizes bilirubin, INR, and creatinine, is the standard for prioritizing liver transplantation and is a frequent point of reference in these vignettes.
Approach to Acute Diarrhea and Infectious Colitis
Distinguishing between inflammatory and non-inflammatory diarrhea is the first step in clinical evaluation. Non-inflammatory diarrhea (e.g., viral, B. cereus, S. aureus) is usually watery and lacks blood or mucus. In contrast, inflammatory diarrhea (e.g., Salmonella, Shigella, Campylobacter, EHEC) often presents with fever and fecal leukocytes. A critical rule for Step 2 CK is to avoid antibiotics in suspected Enterohemorrhagic E. coli (O157:H7) infections, as this can increase the risk of Hemolytic Uremic Syndrome (HUS), characterized by the triad of hemolytic anemia, thrombocytopenia, and acute kidney injury.
Clostridioides difficile infection (CDI) is another high-yield topic. Diagnosis is confirmed via a stool toxin assay or PCR. Management has shifted in recent years; oral vancomycin or fidaxomicin is now preferred over metronidazole for the first episode of non-severe CDI. If the patient has fulminant colitis (hypotension, ileus, or megacolon), the management involves high-dose oral vancomycin, rectal vancomycin, and intravenous metronidazole. Understanding the transition from medical management to surgical consultation for toxic megacolon is a common assessment point for determining clinical judgment.
Infectious Disease and Antimicrobial Stewardship
Empiric Antibiotic Coverage for Common Infections
Infectious disease questions often test the selection of empiric antibiotics based on the site of infection and local resistance patterns. For Community-Acquired Pneumonia (CAP), the treatment for a healthy outpatient is typically amoxicillin, doxycycline, or a macrolide (if local resistance is <25%). However, for hospitalized patients, the standard is a respiratory fluoroquinolone (levofloxacin/moxifloxacin) or a combination of a beta-lactam (ceftriaxone) plus a macrolide (azithromycin). The CURB-65 score is the tool used to decide whether the patient requires inpatient or ICU admission.
Urinary tract infections (UTIs) are equally high-yield. Uncomplicated cystitis in women can be treated with nitrofurantoin, TMP-SMX, or fosfomycin. In cases of pyelonephritis, outpatient treatment involves ciprofloxacin or levofloxacin, while inpatient treatment requires IV ceftriaxone or an aminoglycoside. For skin and soft tissue infections, you must distinguish between non-purulent cellulitis (targeting Streptococcus) and purulent cellulitis/abscess (targeting MRSA). Abscesses primarily require incision and drainage, with antibiotics reserved for systemic symptoms or extensive surrounding cellulitis.
HIV Management and Opportunistic Infection Prophylaxis
HIV management on Step 2 CK focuses on the timing of Antiretroviral Therapy (ART) and the prevention of opportunistic infections (OIs). ART is recommended for all HIV-infected individuals regardless of CD4 count. Prophylaxis guidelines have recently been simplified: TMP-SMX is indicated for Pneumocystis jirovecii pneumonia (PCP) when the CD4 count is <200/mm³. It also provides coverage against Toxoplasma gondii, which requires prophylaxis when CD4 is <100/mm³ and the patient is seropositive for Toxoplasma IgG.
Notably, prophylaxis for Mycobacterium avium complex (MAC) with azithromycin is no longer routinely recommended for patients who are immediately starting ART, even if their CD4 count is <50/mm³. For the exam, you must also recognize the clinical presentation of these OIs. For example, PCP presents with subacute dyspnea and interstitial infiltrates, while Cerebral Toxoplasmosis presents with multiple ring-enhancing lesions on CT or MRI. If a patient with HIV presents with a single ring-enhancing lesion and is EBV DNA positive in the CSF, the diagnosis is more likely Primary CNS Lymphoma.
Sepsis Recognition and Early Goal-Directed Therapy
Sepsis is a medical emergency characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The exam uses the qSOFA (Quick Sequential Organ Failure Assessment) score—consisting of altered mental status, systolic BP ≤100 mmHg, and respiratory rate ≥22/min—to identify patients at risk. Management follows the Surviving Sepsis Campaign bundles. Within the first hour, clinicians must obtain blood cultures (before antibiotics), measure serum lactate, and administer broad-spectrum antibiotics.
If the patient is hypotensive or has a lactate ≥4 mmol/L, an immediate fluid bolus of 30 mL/kg of isotonic crystalloid is required. Use of the Mean Arterial Pressure (MAP) goal of ≥65 mmHg is the standard for gauging response. If hypotension persists despite adequate fluid resuscitation, the patient has entered septic shock and requires vasopressors, with norepinephrine being the first-line choice. The exam frequently tests the recognition that delaying antibiotics for imaging or other diagnostic tests in a septic patient is incorrect management.
Endocrinology: Diabetes and Thyroid Disorders
Glycemic Control Targets and Medication Selection
Diabetes management is a cornerstone of the most tested medicine topics Step 2 CK. The standard A1c goal for most non-pregnant adults is <7.0%. Metformin remains the first-line pharmacologic agent due to its efficacy, weight neutrality, and lack of hypoglycemia risk. However, it must be held in the setting of acute kidney injury or severe contrast-load procedures due to the risk of lactic acidosis.
For patients with established atherosclerotic cardiovascular disease (ASCVD), Heart Failure, or CKD, the exam now prioritizes the addition of SGLT2 inhibitors (e.g., empagliflozin) or GLP-1 receptor agonists (e.g., liraglutide) regardless of whether the A1c is at goal. SGLT2 inhibitors are particularly favored in patients with HFrEF and albuminuric CKD. When transitioning to insulin, the exam often tests the basal-bolus regimen, which mimics physiological insulin secretion. You must also be able to manage acute complications like DKA and HHS, focusing on aggressive IV fluid resuscitation, potassium replacement (before insulin if K+ <3.3 mEq/L), and IV insulin infusion until the anion gap closes.
Thyroid Function Test Interpretation and Management
Thyroid disorders require a systematic approach to Lab interpretation. Primary hypothyroidism is characterized by an elevated TSH and low Free T4, while hyperthyroidism shows a low TSH and elevated Free T4. If TSH is low but Free T4 is normal, you must check T3 levels to rule out T3-toxicosis. For hyperthyroidism, the next step in the workup is often a Radioactive Iodine Uptake (RAIU) scan to differentiate between Graves' disease (diffuse uptake), toxic multinodular goiter (patchy uptake), and thyroiditis (low uptake).
Treatment of Graves' disease involves beta-blockers for symptom control and antithyroid drugs (Methimazole or Propylthiouracil). Note that Methimazole is generally preferred except in the first trimester of pregnancy due to teratogenicity. For hypothyroidism, levothyroxine is the treatment of choice, with dose adjustments based on TSH levels every 6-8 weeks. In elderly patients or those with coronary artery disease, the rule is to "start low and go slow" to avoid precipitating myocardial ischemia through sudden increases in metabolic demand.
Osteoporosis Screening and Treatment Guidelines
Osteoporosis is primarily a disease of postmenopausal women and older men, and screening is performed using Dual-energy X-ray Absorptiometry (DEXA). The USPSTF recommends screening for all women aged 65 and older, and for younger women whose 10-year fracture risk (calculated by the FRAX tool) is equal to or greater than that of a 65-year-old white woman. Osteoporosis is defined by a T-score ≤ -2.5.
First-line treatment consists of bisphosphonates (e.g., alendronate, risedronate), which inhibit osteoclast-mediated bone resorption. Patients must be instructed to take these medications on an empty stomach with a full glass of water and remain upright for 30 minutes to prevent pill-induced esophagitis. For patients who cannot tolerate bisphosphonates or have severe osteoporosis, second-line options include denosumab or teriparatide. The exam may also test the management of osteopenia (T-score between -1.0 and -2.5), where treatment is initiated only if the FRAX score indicates a high risk of major osteoporotic fracture (≥20%) or hip fracture (≥3%).
Pulmonary and Critical Care Topics
COPD and Asthma Exacerbation Management
Acute exacerbations of COPD and asthma are frequent Step 2 CK scenarios. In COPD, an exacerbation is defined by increased sputum volume, increased sputum purulence, or increased dyspnea. Management includes oxygen (targeting 88-92% saturation), inhaled bronchodilators (albuterol/ipratropium), systemic corticosteroids (prednisone), and antibiotics if at least two of the cardinal symptoms are present. If the patient has respiratory acidosis (pH <7.35), Non-invasive Positive Pressure Ventilation (NIPPV) is the next best step and has been shown to reduce mortality and the need for intubation.
For asthma exacerbations, the focus is on the severity of the airflow obstruction. Initial treatment includes inhaled SABA and systemic steroids. The exam often looks for "danger signs" such as a normal PCO2 on an arterial blood gas. In a patient with tachypnea, a normal PCO2 suggests respiratory muscle fatigue and impending respiratory failure, necessitating immediate intensive care monitoring and possible intubation. Unlike COPD, the oxygen target for asthma is typically >90% or >95% in pregnant patients.
Interpretation of Pulmonary Function Tests
Pulmonary Function Tests (PFTs) are essential for distinguishing between obstructive and restrictive lung diseases. An FEV1/FVC ratio <0.70 (or less than the lower limit of normal) defines obstruction. In obstructive cases, the DLCO (Diffusion Capacity of the Lung for Carbon Monoxide) helps differentiate the cause: it is decreased in emphysema due to alveolar destruction but normal or increased in asthma.
Restrictive lung disease is characterized by an FEV1/FVC ratio that is normal or increased, but with a Total Lung Capacity (TLC) <80% of predicted. If the DLCO is decreased in a restrictive pattern, it suggests interstitial lung disease (ILD). If the DLCO is normal, it suggests an extrapulmonary cause of restriction, such as obesity, chest wall deformity (kyphoscoliosis), or neuromuscular weakness (myasthenia gravis). Understanding these patterns allows you to quickly narrow down the differential for chronic dyspnea in a clinical vignette.
Venous Thromboembolism Diagnosis and Anticoagulation
When Pulmonary Embolism (PE) is suspected, the first step is assessing the clinical probability using the Wells Criteria. If the probability is low, a D-dimer test can be used to rule out PE. If the probability is high, the next step is a CT Pulmonary Angiography (CTPA). If the patient has a contraindication to CTPA, such as renal failure or contrast allergy, a Ventilation/Perfusion (V/Q) scan is the appropriate alternative.
Management of VTE (DVT or PE) involves anticoagulation. In hemodynamically stable patients, Direct Oral Anticoagulants (DOACs) like rivaroxaban or apixaban are now first-line. For patients with malignancy, low-molecular-weight heparin (LMWH) was historically preferred, though DOACs are now often used. If a patient is hemodynamically unstable (systolic BP <90 mmHg), they have a "massive PE" and require thrombolysis or embolectomy. If anticoagulation is contraindicated (e.g., active GI bleed), an IVC filter should be placed. The duration of therapy is typically 3 months for a provoked VTE and indefinitely for unprovoked or recurrent events.
Rheumatology and Nephrology for the Clinician
Diagnosis and Treatment of Common Rheumatologic Diseases
Rheumatology on Step 2 CK focuses on the clinical patterns of joint involvement and extra-articular manifestations. Rheumatoid Arthritis (RA) presents as a symmetric, small-joint polyarthritis with morning stiffness lasting >1 hour. The most specific lab is anti-CCP antibodies. Treatment should start early with Disease-Modifying Antirheumatic Drugs (DMARDs), with methotrexate being the first-line choice. Before starting methotrexate, you must check for liver disease, lung disease, and pregnancy.
Systemic Lupus Erythematosus (SLE) is tested through its multisystem involvement (malar rash, arthritis, nephritis, serositis). While ANA is sensitive, anti-dsDNA and anti-Smith are specific. Acute flares are managed with steroids, but hydroxychloroquine is the backbone of long-term therapy to reduce flares and improve survival. For crystal-induced arthropathies, gout is diagnosed via synovial fluid analysis showing needle-shaped, negatively birefringent crystals. Acute gout is treated with NSAIDs, colchicine, or steroids, while chronic management focuses on urate-lowering therapy like allopurinol, which should not be started during an acute flare unless the patient is already taking it.
Chronic Kidney Disease Staging and Slowing Progression
CKD is defined by a GFR <60 mL/min/1.73m² or markers of kidney damage (like albuminuria) for >3 months. The exam focuses on preventing the progression to End-Stage Renal Disease (ESRD). The two most critical interventions are blood pressure control and the use of ACE inhibitors or ARBs, particularly in patients with a Urine Albumin-to-Creatinine Ratio (UACR) ≥30 mg/g. These agents dilate the efferent arteriole, reducing intraglomerular pressure.
Management of CKD complications is also high-yield. For anemia of CKD, which is typically normocytic and due to decreased erythropoietin production, erythropoiesis-stimulating agents (ESAs) are used, but only when hemoglobin is <10 g/dL to avoid cardiovascular risks. For secondary hyperparathyroidism, the focus is on phosphate binders (e.g., sevelamer) and vitamin D analogues (e.g., calcitriol). You must also recognize the indications for urgent dialysis, often remembered by the mnemonic AEIOU: Acidosis (refractory), Electrolytes (refractory hyperkalemia), Intoxications (lithium, ethylene glycol), Overload (refractory volume), and Uremia (pericarditis, encephalopathy, or asterixis).
Electrolyte Disorder Correction and Fluid Management
Hyponatremia is the most frequently tested electrolyte disorder. The first step is determining serum osmolality to rule out pseudohyponatremia. If the patient is truly hypotonic, you must assess volume status. SIADH (euvolemic hyponatremia) is common in Step 2 vignettes, often triggered by CNS disease, pulmonary disease, or medications (SSRIs). Treatment for SIADH involves fluid restriction. For severe, symptomatic hyponatremia (seizures, coma), 3% hypertonic saline is used. A critical rule is to avoid correcting sodium faster than 0.5 mEq/L/hr to prevent Central Pontine Myelinolysis (Osmotic Demyelination Syndrome).
Hyperkalemia is another emergency, often presenting with peaked T-waves on EKG. The management sequence is vital: first, stabilize the cardiac membrane with intravenous calcium gluconate; second, shift potassium into cells using insulin (with glucose) and albuterol; and third, remove potassium from the body using loop diuretics, cation exchangers (e.g., patiromer), or dialysis. Identifying the underlying cause, such as medications (ACEi, NSAIDs, spironolactone) or AKI, is essential for long-term prevention. Understanding the nuances of fluid resuscitation—using isotonic crystalloids for volume depletion and avoiding hypotonic fluids in patients with increased intracranial pressure—is a fundamental skill for the internal medicine clinical knowledge Step 2 portion of the exam.